Home » Topics » BioWorld Science, Patents

BioWorld Science, Patents
RSS

Fibrinogen antagonist research continues at Merck & Co.

Oct. 11, 1996

MTP inhibitors from Bristol-Myers Squibb

Oct. 11, 1996

Wakunaga discloses angiotensin II antagonists

Oct. 11, 1996

Endothelin antagonists from Banyu

Oct. 11, 1996

Warner-Lambert claims endothelin antagonists

Oct. 11, 1996

Dual thromboxane synthase/lipoxygenase inhibitors from Nikken Chemicals

Oct. 11, 1996

Calpain inhibitors reported by Warner-Lambert

Oct. 11, 1996

New muscarinic antagonists from Schering-Plough

Oct. 11, 1996

Potential antipsychotic agents disclosed by Pharmacia & Upjohn

Oct. 11, 1996

Dopamine D3 ligands from Pharmacia & Upjohn

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.